Treatment Syndromes Dementia Movement Disorders Market

Table of Content

Chapter 1. Preface

    1.1. Report Description

    1.2. Research Methodology

    1.3. Assumptions

Chapter 2. Market Synopsis

Chapter 3. Porter’s Five Forces Analysis

    3.1. Bargaining Power of Suppliers

    3.2. Bargaining Power of Buyers

    3.3. Threat of New Entrants

    3.4. Threat of Substitutes

    3.5. Intensity of Rivalry

Chapter 4. Industry Overview

    4.1. Market Definition

    4.2. Market Drivers

        4.2.1. Increasing prevalence of neurodegenerative diseases

        4.2.2. Rising awareness about mental diseases

        4.2.3. Increasing R&D investments in drug discovery and developments

    4.3. Impact Analysis of Market Drivers

    4.4. Market Restraints

        4.4.1. Strict regulatory requirements and long approval time for drugs

        4.4.2. Lack of comprehensive therapeutic management of dementia and movement disorders

    4.5. Impact Analysis of Market Restraints

    4.6. Market Trend

        4.6.1. Rising number of collaborations and partnerships would lead to rise in research and discovery of dementia and movement disorder drugs

Chapter 5. Global Market Size and Forecast

Chapter 6. Market Size and Forecast by Drugs Used to Treat Progressive Dementia

    6.1. Diseases Based Therapeutics Under Progressive Dementia

    6.2. Drugs for Progressive Dementia

Chapter 7. Market Size and Forecast by Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities

    7.1. Diseases Based Therapeutics Under Progressive Dementia with Other Neurological Abnormalities

    7.2. Drugs for Progressive Dementia

Chapter 8. Market Size and Forecast by Drugs Used to Treat Movement Disorder Syndrome

    8.1. Diseases Based Therapeutics Under Movement Disorder Syndrome

    8.2. Drugs for Movement Disorder Syndrome

Chapter 9. Market Size and Forecast by Geography

    9.1. North America

    9.2. Europe

    9.3. Asia

Chapter 10. Competitive Scenario

    10.1. Competitive Benchmarking

Chapter 11. Company Profiles

    11.1. F. Hoffmann-La Roche, Ltd.

        11.1.1. Company overview

        11.1.2. Products and services

        11.1.3. Financial performance

        11.1.4. Key developments

    11.2. Baxter

        11.2.1. Company overview

        11.2.2. Products and services

        11.2.3. Financial performance

        11.2.4. Key development

    11.3. Novartis AG

        11.3.1. Company overview

        11.3.2. Products and services

        11.3.3. Financial performance

        11.3.4. Key developments

    11.4. Merck & Co., Inc.

        11.4.1. Company overview

        11.4.2. Products and services

        11.4.3. Financial performance

        11.4.4. Key developments

    11.5. Sanofi

        11.5.1. Company overview

        11.5.2. Products and services

        11.5.3. Financial performance

        11.5.4. Key developments

    11.6. Pfizer, Inc.

        11.6.1. Company overview

        11.6.2. Products and services

        11.6.3. Financial performance

        11.6.4. Key developments

    11.7. Valeant Pharmaceuticals International, Inc.

        11.7.1. Company overviews

        11.7.2. Products and services

        11.7.3. Financial performance

        11.7.4. Key developments

    11.8. AstraZeneca GmbH

        11.8.1. Company overview

        11.8.2. Products and services

        11.8.3. Financial performance

        11.8.4. Key developments

    11.9. Abbott Laboratories, Inc.

        11.9.1. Company overview

        11.9.2. Products and services

        11.9.3. Financial performance

        11.9.4. Key developments

    11.10. Bristol-Myers Squibb Company

        11.10.1. Company overview

        11.10.2. Products and services

        11.10.3. Financial performance

        11.10.4. Key developments

List Of Table

List of Tables

TABLE 1: Market snapshot: Treatment for syndromes of dementia and movement disorders market, 2014 and 2020

TABLE 2: Drivers for global treatment for syndrome of dementia and movement disorders market: Impact analysis

TABLE 3: Estimated average timelines for clinical trial approval in various countries

TABLE 4: Restraints for global treatment for syndromes of dementia and movement disorders market: Impact analysis

TABLE 5: Major collaborations and partnerships by dementia and movement disorder treatment companies (2011 – 2013)

TABLE 6: Global treatments for syndromes of dementia and movement disorders market size, by region, 2010 – 2013 (USD million)

TABLE 7: Global treatments for syndromes of dementia and movement disorders market size, by region, 2014 – 2020 (USD million)

TABLE 8: Global treatments for syndromes of dementia and movement disorders market size, by segment, 2010 – 2013 (USD million)

TABLE 9: Global treatments for syndromes of dementia and movement disorders market size, by segment, 2014 – 2020 (USD million)

TABLE 10: Global progressive dementia therapeutic market size, by disease, 2010 – 2013 (USD million)

TABLE 11: Global progressive dementia therapeutic market size, by disease, 2014 – 2020 (USD million)

TABLE 12: Global progressive dementia market size, by drug category, 2010 – 2013 (USD million)

TABLE 13: Global progressive dementia market size, by drug category, 2014 – 2020 (USD million)

TABLE 14: Global progressive dementia with other neurological abnormalities therapeutics market size, by disease, 2010 – 2013 (USD million)

TABLE 15: Global progressive dementia with other neurological abnormalities therapeutic market size, by disease, 2014 – 2020 (USD million)

TABLE 16: Global progressive dementia with other neurological abnormalities market size, by drug category, 2010 – 2013 (USD million)

TABLE 17: Global progressive dementia with other neurological abnormalities market size, by drug category, 2014 – 2020 (USD million)

TABLE 18: Global movement disorder syndrome therapeutics market size, by disease, 2010 – 2013 (USD million)

TABLE 19: Global movement disorder syndrome therapeutics market size, by disease, 2014 – 2020 (USD million)

TABLE 20: Global movement disorders market size, by drug category, 2010 – 2013 (USD million)

TABLE 21: Global movement disorder market size, by drug category, 2014 – 2020 (USD million)

TABLE 22: The North American treatment for syndromes of dementia and movement disorders market size, by country, 2010 – 2013 (USD million)

TABLE 23: The North American treatment for syndromes of dementia and movement disorders market size, by country, 2014 – 2020 (USD million)

TABLE 24: The North American treatments for syndromes of dementia and movement disorders market size, by segment, 2010 – 2013 (USD million)

TABLE 25: The North American treatments for syndromes of dementia and movement disorders market size, by segment, 2014 – 2020 (USD million)

TABLE 26: The European treatment for syndromes of dementia and movement disorders market size, by country, 2010 – 2013 (USD million)

TABLE 27: The European treatment for syndromes of dementia and movement disorders market size, by country, 2014 – 2020 (USD million)

TABLE 28: The European treatments for syndromes of dementia and movement disorders market size, by segment, 2010 – 2013 (USD million)

TABLE 29: The European treatments for syndromes of dementia and movement disorders market size, by segment, 2014 – 2020 (USD million)

TABLE 30: The Asian treatment for syndromes of dementia and movement disorders market size, by country, 2010 – 2013 (USD million)

TABLE 31: The Asian treatment for syndromes of dementia and movement disorders market size, by country, 2014 – 2020 (USD million)

TABLE 32: The Asian treatments for syndromes of dementia and movement disorders market size, by segment, 2010 – 2013 (USD million)

TABLE 33: The Asian treatments for syndromes of dementia and movement disorders market size, by segment, 2014 – 2020 (USD million)

TABLE 34: F. Hoffmann-La Roche, Ltd.’s product categories

TABLE 35: Baxter’s product categories

TABLE 36: Novartis AG’s product categories

TABLE 37: Merck & Co., Inc.’s product categories

TABLE 38: Sanofi’s product categories

TABLE 39: Pfizer, Inc.’s product categories

TABLE 40: Valeant Pharmaceuticals International, Inc.’s product categories

TABLE 41: AstraZeneca GmbH’s product categories

TABLE 42: Abbott Laboratories, Inc.’s product categories

TABLE 43: Bristol-Myers Squibb Company’s product categories

- List Of Chart -

List of Figures

FIG. 1: Treatment for syndromes of dementia and movement disorders market: Porter’s five forces analysis

FIG. 2: Types of dementia and movement disorders 18

FIG. 3: Global treatments for syndromes of dementia and movement disorders market share, by region, by value, 2013

FIG. 4: Global treatments for syndromes of dementia and movement disorders market share, by segment, by value, 2013

FIG. 5: Global progressive dementia therapeutic market share, by disease, by value, 2013

FIG. 6: Global progressive dementia market share, by drug category, by value, 2013

FIG. 7: Global progressive dementia with other neurological abnormalities therapeutics market share, by disease, by value, 2013

FIG. 8: Global progressive dementia with other neurological abnormalities market share, by drug category, by value, 2013

FIG. 9: Global movement disorder syndrome therapeutics market share, by disease, by value, 2013

FIG. 10: Global movement disorder syndrome market share, by drug category, by value, 2013

FIG. 11: The North American treatment for syndromes of dementia and movement disorders market share, by country, by value, 2013

FIG. 12: The North American treatments for syndromes of dementia and movement disorders market share, by segment, by value, 2013

FIG. 13: The European treatment for syndromes of dementia and movement disorders market share, by country, by value, 2013

FIG. 14: The European treatments for syndromes of dementia and movement disorders market share, by segment, by value, 2013

FIG. 15: The Asian treatment for syndromes of dementia and movement disorders market share, by country, by value, 2013

FIG. 16: The Asian treatments for syndromes of dementia and movement disorders market share, by segment, by value, 2013

FIG. 17: Competitive landscape of treatment providers for syndromes of dementia and movement disorders, 2013

FIG. 18: F. Hoffmann-La Roche, Ltd.’s sales and net income, 2011 – 2013 (USD million)

FIG. 19: Baxter’s net sales and net income, 2011 – 2013 (USD million)

FIG. 20: Novartis AG’s net sales and net income, 2011 – 2013 (USD million)

FIG. 21: Merck & Co., Inc.’s sales and net income, 2011 – 2013 (USD million)

FIG. 22: Sanofi net sales and net income, 2011 – 2013 (USD million)

FIG. 23: Pfizer, Inc.’s revenue and net income, 2011 – 2013 (USD million)

FIG. 24: Valeant Pharmaceuticals International, Inc.’s revenues and net income/loss, 2011 – 2013 (USD million)

FIG. 25: AstraZeneca GmbH’s revenues and profit, 2011 – 2013 (USD million)

FIG. 26: Abbott Laboratories’ net sales and net earnings, 2011 – 2013 (USD million)

FIG. 27: Bristol-Myers Squibb’s revenue and net earnings, 2011 – 2013 (USD million)